Business combinations (Tables)

9 Months Ended

Sep. 30, 2012

Micromet, Inc. [Member]

Allocation of the total consideration to the acquisition date fair values of assets acquired and liabilities assumed

The consideration to acquire Micromet totaled $1,146 million in cash which was allocated to the acquisition date fair values of assets acquired and liabilities assumed as follows (in millions):



Indefinite-lived intangible assets:
In-process research and development (IPR&D)	$	440
Contract assets	170
Finite-lived intangible assets — Developed technology	350
Goodwill	330
Cash and marketable securities	154
Deferred tax assets	43
Deferred tax liabilities	(317		)
Other assets (liabilities), net	(24		)
Total consideration	$	1,146

Mustafa Nevzat Pharmaceuticals [Member]

Business Combinations [Line Items]

Allocation of the total consideration to the acquisition date fair values of assets acquired and liabilities assumed

The consideration to acquire MN totaled $677 million in cash which was allocated to the acquisition date fair values of assets acquired and liabilities assumed as follows (in millions):



Finite-lived intangible assets	$	163
Property, plant and equipment	100
Trade receivables	79
Inventories	52
Goodwill	382
Deferred tax liabilities	(45		)
Other assets (liabilities), net	(54		)
Total consideration	$	677

KAI Pharmaceuticals [Member]

Business Combinations [Line Items]

Allocation of the total consideration to the acquisition date fair values of assets acquired and liabilities assumed

The consideration to acquire KAI totaled $332 million in cash which was allocated to the acquisition date fair values of assets acquired and liabilities assumed as follows (in millions):



Indefinite-lived intangible assets - IPR&D	$	260
Goodwill	146
Deferred tax liabilities	(100		)
Other assets (liabilities), net	26
Total consideration	$	332